1. Monocyte and microglial activation in patients with mood-stabilized bipolar disorder.

    Journal of Psychiatry and Neuroscience 40(4):250 (2015) PMID 25768030 PMCID PMC4478058

    Bipolar disorder is associated with medical comorbidities that have been linked to systemic inflammatory mechanisms. There is, however, limited evidence supporting a role of neuroinflammation in bipolar disorder. Here we tested whether microglial activation and associated tissue remodelling proc...
  2. First effects of rising amyloid-β in transgenic mouse brain: synaptic transmission and gene expression.

    Brain 138(Pt 7):1992 (2015) PMID 25981962

    Detecting and treating Alzheimer's disease, before cognitive deficits occur, has become the health challenge of our time. The earliest known event in Alzheimer's disease is rising amyloid-β. Previous studies have suggested that effects on synaptic transmission may precede plaque deposition. Here...
  3. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.

    Alzheimer's & Dementia 11(7):772 (2015) PMID 26194312

    We describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ1-42), t-tau, and p-tau181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and i...
  4. Explorative and targeted neuroproteomics in Alzheimer's disease.

    Biochimica et Biophysica Acta 1854(7):769 (2015) PMID 25619854

    Alzheimer's disease (AD) is a progressive brain amyloidosis that injures brain regions involved in memory consolidation and other higher brain functions. Neuropathologically, the disease is characterized by accumulation of a 42 amino acid peptide called amyloid β (Aβ42) in extracellular senile p...
  5. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
    Willemijn Jansen, Rik Ossenkoppele, Dirk L Knol, Betty M Tijms, Philip Scheltens, Frans R J Verhey, Pieter Jelle Visser, Pauline Aalten, Dag Aarsland, Daniel Alcolea, Myriam Alexander, Ina S Almdahl, Steven E Arnold, Inês Baldeiras, Henryk Barthel, Bart N M van Berckel, Kristen Bibeau, Kaj Blennow, David J Brooks, Mark A van Buchem, Vincent Camus, Enrica Cavedo, Kewei Chen, Gael Chetelat, Ann D Cohen, Alexander Drzezga, Sebastiaan Engelborghs, Anne M Fagan, Tormod Fladby, Adam S Fleisher, Wiesje M van der Flier, Lisa Ford, Stefan Förster, Juan Fortea, Nadia Foskett, Kristian S Frederiksen, Yvonne Freund-Levi, Giovanni B Frisoni, Lutz Froelich, Tomasz Gabryelewicz, Kiran Dip Gill, Olymbia Gkatzima, Estrella Gómez-Tortosa, Mark Forrest Gordon, Timo Grimmer, Harald Hampel, Lucrezia Hausner, Sabine Hellwig, Sanna-Kaisa Herukka, Helmut Hildebrandt, Lianna Ishihara, Adrian Ivanoiu, William Jagust, Peter Johannsen, Ramesh Kandimalla, Elisabeth Kapaki, Aleksandra Klimkowicz-Mrowiec, William E Klunk, Sebastian Köhler, Norman Koglin, Johannes Kornhuber, Milica G Kramberger, Koen Van Laere, Susan M Landau, Dong Young Lee, Mony de Leon, Viviana Lisetti, Alberto Lleó, Karine Madsen, Wolfgang Maier, Jan Marcusson, Niklas Mattsson, Alexandre de Mendonça, Olga Meulenbroek, Philipp T Meyer, Mark A Mintun, Vincent Mok, José Luis Molinuevo, Hanne Møllergård, John C Morris, Barbara Mroczko, Stefan Van der Mussele, Duk L Na, Andrew Newberg, Agneta Nordberg, Arto Nordlund, Gerald P Novak, George Paraskevas, Lucilla Parnetti, Gayan Perera, Oliver Peters, Julius Popp, Sudesh Prabhakar, Gil D Rabinovici, Inez H G B Ramakers, Lorena Rami, Catarina Resende de Oliveira, Juha O Rinne, Karen M Rodrigue, Eloy, Catherine M Roe, Uros Rot, Christopher Rowe, Eckart Rüther, Osama Sabri, Páscual Sanchez-Juan, Isabel Santana, Marie Sarazin, Johannes Schröder, Christin Schütte, Sang W Seo, Femke Soetewey, Hilkka Soininen, Luiza Spiru, Hanne Struyfs, Charlotte E Teunissen, Magda Tsolaki, Rik Vandenberghe, Marcel Verbeek, Victor L Villemagne, Stephanie J B Vos, Linda J C van Waalwijk Doorn, Gunhild Waldemar, Anders Wallin, Åsa K Wallin, Jens Wiltfang, David A Wolk, Marzena Zboch, and Henrik Zetterberg

    JAMA 313(19):1924 (2015) PMID 25988462 PMCID PMC4486209

    Cerebral amyloid-β aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies. To use in...
  6. APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons.

    Cell Reports 11(5):689 (2015) PMID 25921538 PMCID PMC4431668

    Accumulation of Aβ peptide fragments of the APP protein and neurofibrillary tangles of the microtubule-associated protein tau are the cellular hallmarks of Alzheimer's disease (AD). To investigate the relationship between APP metabolism and tau protein levels and phosphorylation, we studied huma...
  7. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research.

    Alzheimer's & Dementia 11(5):549 (2015) PMID 25282381 PMCID PMC4414664

    The lack of readily available biomarkers is a significant hindrance toward progressing to effective therapeutic and preventative strategies for Alzheimer's disease (AD). Blood-based biomarkers have potential to overcome access and cost barriers and greatly facilitate advanced neuroimaging and ce...
  8. Amyloid biomarkers in Alzheimer's disease.

    Trends in Pharmacological Sciences 36(5):297 (2015) PMID 25840462

    Aggregation of amyloid-β (Aβ) into oligomers, fibrils, and plaques is central in the molecular pathogenesis of Alzheimer's disease (AD), and is the main focus of AD drug development. Biomarkers to monitor Aβ metabolism and aggregation directly in patients are important for further detailed study...
  9. Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease.

    Alzheimer's & Dementia 11(4):455 (2015) PMID 24751826

    Health-care stakeholders increasingly recognize that the scientific and economic challenges associated with Alzheimer's disease (AD) are simply too great for individual stakeholder groups to address solely from within their own silos. In the necessary spirit of collaboration, we present in this ...
  10. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.

    Multiple Sclerosis Journal 21(5):550 (2015) PMID 25732842 PMCID PMC4390605

    To investigate glial and neuronal biomarkers in cerebrospinal fluid (CSF) samples from patients with relapsing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) suggestive of multiple sclerosis (MS), and to evaluate their ability to predict conversion from CIS to clinica...
  11. Understanding Biomarkers of Neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding.

    Nature Medicine 21(3):217 (2015) PMID 25742456

  12. A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals

    Neuropsychologia 69:1 (2015)

    Delayed recall at the primacy position (first few items on a list) has been shown to predict cognitive decline in cognitively intact elderly participants, with poorer delayed primacy performance associated with more pronounced generalized cognitive decline during follow-up. We have pre...
  13. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.

    Brain 138(Pt 3):772 (2015) PMID 25541191

    Reduced cerebrospinal fluid amyloid-β42 and increased retention of florbetapir positron emission tomography are biomarkers reflecting cortical amyloid load in Alzheimer's disease. However, these measurements do not always agree and may represent partly different aspects of the underlying Alzheim...
  14. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.

    Brain 138(Pt 3):772 (2015) PMID 25541191 PMCID PMC4339769

    Reduced cerebrospinal fluid amyloid-β42 and increased retention of florbetapir positron emission tomography are biomarkers reflecting cortical amyloid load in Alzheimer's disease. However, these measurements do not always agree and may represent partly different aspects of the underlying Alzheim...
  15. A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals.

    Neuropsychologia 69:1 (2015) PMID 25613646

    Delayed recall at the primacy position (first few items on a list) has been shown to predict cognitive decline in cognitively intact elderly participants, with poorer delayed primacy performance associated with more pronounced generalized cognitive decline during follow-up. We have previously su...
  16. A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals.

    Neuropsychologia 69:1 (2015) PMID 25613646 PMCID PMC4344890

    Delayed recall at the primacy position (first few items on a list) has been shown to predict cognitive decline in cognitively intact elderly participants, with poorer delayed primacy performance associated with more pronounced generalized cognitive decline during follow-up. We have previously su...
  17. A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals.

    Neuropsychologia 69:1 (2015) PMID 25613646

    Delayed recall at the primacy position (first few items on a list) has been shown to predict cognitive decline in cognitively intact elderly participants, with poorer delayed primacy performance associated with more pronounced generalized cognitive decline during follow-up. We have previously su...
  18. An Integrated Workflow for Multiplex CSF Proteomics and Peptidomics-Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimer's Disease.

    Journal of Proteome Research 14(2):654 (2015) PMID 25490617

    Many disease processes in the brain are reflected in the protein composition of the cerebrospinal fluid (CSF). In addition to proteins, CSF also contains a large number of endogenous peptides whose potential as disease biomarkers largely remains to be explored. We have developed a novel workflow...
  19. An Integrated Workflow for Multiplex CSF Proteomics and Peptidomics-Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimer's Disease.

    Journal of Proteome Research 14(2):654 (2015) PMID 25490617

    Many disease processes in the brain are reflected in the protein composition of the cerebrospinal fluid (CSF). In addition to proteins, CSF also contains a large number of endogenous peptides whose potential as disease biomarkers largely remains to be explored. We have developed a novel workflow...
  20. Rarity of the Alzheimer Disease-Protective APP A673T Variant in the United States.
    Li-San Wang, Adam C Naj, Robert Graham, Paul K Crane, Brian W Kunkle, Carlos Cruchaga, Josue D Gonzalez Murcia, Lisa Cannon-Albright, Clinton T Baldwin, Henrik Zetterberg, Kaj Blennow, Walter A Kukull, Kelley M Faber, Nicole Schupf, Maria C Norton, JoAnn Tschanz, Ronald G Munger, Christopher D Corcoran, Ekaterina Rogaeva, Chiao-Feng Lin, Beth A Dombroski, Laura B Cantwell, Amanda Partch, Otto Valladares, Hakon Hakonarson, Peter St George-Hyslop, Robert C Green, Alison M Goate, Tatiana M Foroud, Regina M Carney, Eric B Larson, Timothy W Behrens, John S Kauwe, Jonathan L Haines, Lindsay A Farrer, Margaret A Pericak-Vance, Richard Mayeux, Gerard D Schellenberg, Marilyn S Albert, Roger L Albin, Liana G Apostolova, Steven E Arnold, Robert Barber, Michael Barmada, Lisa Barnes, Thomas G Beach, James T Becker, Gary W Beecham, Duane Beekly, David A Bennett, Eileen H Bigio, Thomas D Bird, Deborah Blacker, Bradley F Boeve, James D Bowen, Adam Boxer, James R Burke, Joseph D Buxbaum, Nigel J Cairns, Chuanhai Cao, Chris S Carlson, Steven L Carroll, Helena Chui, David G Clark, David H Cribbs, Elizabeth A Crocco, Charles DeCarli, Steven T DeKosky, F Yesim Demirci, Malcolm Dick, Dennis W Dickson, Ranjan Duara, Nilufer Ertekin-Taner, Kenneth B Fallon, Martin R Farlow, Steven Ferris, Matthew P Frosch, Douglas R Galasko, Mary Ganguli, Marla Gearing, Daniel H Geschwind, Bernardino Ghetti, John R Gilbert, Jonathan D Glass, Neill R Graff-Radford, John H Growdon, Ronald L Hamilton, Kara L Hamilton-Nelson, Lindy E Harrell, Elizabeth Head, Lawrence S Honig, Christine M Hulette, Bradley T Hyman, Gail P Jarvik, Gregory A Jicha, Lee-Way Jin, Gyungah Jun, M Ilyas Kamboh, Anna Karydas, Jeffrey A Kaye, Ronald Kim, Edward H Koo, Neil W Kowall, Joel H Kramer, Patricia Kramer, Frank M LaFerla, James Lah, James B Leverenz, Allan I Levey, Ge Li, Andrew P Lieberman, Oscar Lopez, Kathryn Lunetta, Constantine G Lyketsos, Wendy J Mack, Daniel C Marson, Eden R Martin, Frank Martiniuk, Deborah C Mash, Eliezer Masliah, Wayne C McCormick, Susan McCurry, Andrew N McDavid, Ann C McKee, Marsel Mesulam, Bruce L Miller, Carol A Miller, Joshua W Miller, Thomas J Montine, John C Morris, Jill R Murrell, John M Olichney, Joseph E Parisi, William Perry, Elaine Peskind, Ronald C Petersen, Aimee Pierce, Wayne Poon, Huntington Potter, Joseph F Quinn, Ashok Raj, Murray Raskind, Eric M Reiman, Barry Reisberg, Christiane Reitz, John M Ringman, Erik D Roberson, Howard J Rosen, Roger N Rosenberg, Mary Sano, Andrew J Saykin, Julie A Schneider, Lon Schneider, William Seeley, Amanda G Smith, Joshua A Sonnen, Salvatore Spina, Robert A Stern, Rudolph E Tanzi, Tricia A Thornton-Wells, John Q Trojanowski, Juan C Troncoso, Debby W Tsuang, Vivianna M Van Deerlin, Linda J Van Eldik, Badri N Vardarajan, Harry Vinters, Jean Paul Vonsattel, Sandra Weintraub, Kathleen A Welsh-Bohmer, Jennifer Williamson, Sarah Wishnek, Randall L Woltjer, Clinton B Wright, Steven G Younkin, Chang-En Yu, and Lei Yu

    JAMA Neurology 72(2):209 (2015) PMID 25531812

    Recently, a rare variant in the amyloid precursor protein gene (APP) was described in a population from Iceland. This variant, in which alanine is replaced by threonine at position 673 (A673T), appears to protect against late-onset Alzheimer disease (AD). We evaluated the frequency of this varia...